A European Multicenter Randomized Noninferiority Trial Comparing 180 W GreenLight XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Month Results of the GOLIATH Study

Abstract

We recently published a prospective randomized trial (GOLIATH) comparing 180 W GreenLight XPS laser vaporization to TURP for the treatment of men with nonneurogenic lower urinary tract symptoms presumed secondary to benign prostate enlargement.¹ x 1 Bachmann, A., Tubaro, A., Barber, N. et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial–the GOLIATH study. Eur Urol. 2014; 65: 931 Abstract | Full Text | Full Text PDF | PubMed | Scopus (90) | Google Scholar See all References The GOLIATH study investigates whether GL-XPS is noninferior to TURP over several primary outcome measures including I-PSS, Qmax and proportion of patients free of complications. The 6-month data showed GL-XPS vaporization of the prostate to be noninferior to TURP with respect to improvement in I-PSS, Qmax and proportion of patients free of complications. Time to stable health status, catheterization time, length of hospitalization and immediate (within 30 days) surgical reintervention rate were statistically significantly in favor of GL-XPS.¹ x 1 Bachmann, A., Tubaro, A., Barber, N. et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial–the GOLIATH study. Eur Urol. 2014; 65: 931 Abstract | Full Text | Full Text PDF | PubMed | Scopus (90) | Google Scholar See all References